Literature DB >> 33716626

The Role of Innate Immunity in the Pathogenesis of Breast Cancer.

Damir Grebić1, Tamara Gulić2, Alma Starčević3, Manuela Alvirović4, Gordana Blagojević Zagorac2, Petra Valković Zujić5, Danijela Veljković Vujaklija5.   

Abstract

BACKGROUND: Breast carcinoma is the most common malignant disease in the female population and one of the leading causes of death among women worldwide. One crucial hallmark of cancer is chronic inflammation where the immunosuppressive environment is dominant. The immunosuppressive environment is largely achieved by the interaction of tumor cells and infiltrating leukocytes.
SUMMARY: Usually, human macrophages and natural killer cells are involved in antitumor immunity. The therapeutic potential of this population against cancers has stimulated their study and led to the discovery of several different tumor-associated macrophages and natural killer cell subsets, each of which is endowed with different immunoregulatory functions. Both heterogeneity and plasticity of the tumor-associated macrophages and natural killer cell compartment, which are both tightly linked to the tumor microenvironment of different breast cancer types. KEY MESSAGES: The identification of specific tumor-associated macrophages and natural killer cell subsets endowed with particular functional capabilities might help monitor tumor-mediated responses in breast cancer patients. Currently, one of the most used strategies for breast cancer of newly diagnosed patients is neoadjuvant chemotherapy.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; Immunotherapy; Natural killer cells; Tumor microenvironment; Tumor-associated macrophages

Year:  2020        PMID: 33716626      PMCID: PMC7923900          DOI: 10.1159/000507314

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  38 in total

1.  Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Authors:  Rico D Bense; Christos Sotiriou; Martine J Piccart-Gebhart; John B A G Haanen; Marcel A T M van Vugt; Elisabeth G E de Vries; Carolien P Schröder; Rudolf S N Fehrmann
Journal:  J Natl Cancer Inst       Date:  2016-10-13       Impact factor: 13.506

2.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

Authors:  David G DeNardo; Donal J Brennan; Elton Rexhepaj; Brian Ruffell; Stephen L Shiao; Stephen F Madden; William M Gallagher; Nikhil Wadhwani; Scott D Keil; Sharfaa A Junaid; Hope S Rugo; E Shelley Hwang; Karin Jirström; Brian L West; Lisa M Coussens
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

3.  Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.

Authors:  Laura Bonapace; Marie-May Coissieux; Jeffrey Wyckoff; Kirsten D Mertz; Zsuzsanna Varga; Tobias Junt; Mohamed Bentires-Alj
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

4.  Immunosurveillance and Immunoediting of Breast Cancer via Class I MHC Receptors.

Authors:  Megan M Tu; Mir Munir A Rahim; Céline Sayed; Ahmad Bakur Mahmoud; Andrew P Makrigiannis
Journal:  Cancer Immunol Res       Date:  2017-09-18       Impact factor: 11.151

Review 5.  Mutational analysis of breast cancer: guiding personalized treatments.

Authors:  Matthew J Ellis
Journal:  Breast       Date:  2013-08       Impact factor: 4.380

6.  The cellular and molecular origin of tumor-associated macrophages.

Authors:  Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li
Journal:  Science       Date:  2014-05-08       Impact factor: 47.728

7.  A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.

Authors:  Elena Muraro; Debora Martorelli; Elisa Turchet; Gianmaria Miolo; Simona Scalone; Elisa Comaro; Renato Talamini; Katy Mastorci; Davide Lombardi; Tiziana Perin; Antonino Carbone; Andrea Veronesi; Diana Crivellari; Riccardo Dolcetti
Journal:  Breast Cancer Res       Date:  2011       Impact factor: 6.466

8.  Development of a unique small molecule modulator of CXCR4.

Authors:  Zhongxing Liang; Weiqiang Zhan; Aizhi Zhu; Younghyoun Yoon; Songbai Lin; Maiko Sasaki; Jan-Michael A Klapproth; Hua Yang; Hans E Grossniklaus; Jianguo Xu; Mauricio Rojas; Ronald J Voll; Mark M Goodman; Richard F Arrendale; Jin Liu; C Chris Yun; James P Snyder; Dennis C Liotta; Hyunsuk Shim
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

Review 9.  Targeting the CCL2-CCR2 signaling axis in cancer metastasis.

Authors:  Su Yin Lim; Arseniy E Yuzhalin; Alex N Gordon-Weeks; Ruth J Muschel
Journal:  Oncotarget       Date:  2016-05-10

10.  PD-L1 blockade enhances anti-tumor efficacy of NK cells.

Authors:  Jeremiah L Oyer; Sarah B Gitto; Deborah A Altomare; Alicja J Copik
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

View more
  1 in total

1.  Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting.

Authors:  Elena Sultova; C Benedikt Westphalen; Andreas Jung; Joerg Kumbrink; Thomas Kirchner; Doris Mayr; Martina Rudelius; Steffen Ormanns; Volker Heinemann; Klaus H Metzeler; Philipp A Greif; Anna Hester; Sven Mahner; Nadia Harbeck; Rachel Wuerstlein
Journal:  Diagnostics (Basel)       Date:  2021-04-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.